Physician profile
Christopher Buzas
NPI 1790943090
$25,274.68
in general payments reported to CMS, 2019-2025
7 companies · $1,409 in 2025
The $1,409 reported for 2025 was more than what 77% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $357 · 2021: $636 · 2022: $155 · 2023: $2,560 · 2024: $9,916 · 2025: $1,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,807 · Travel and Lodging: $2,057 · Food and Beverage: $1,970 · Gift: $50.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,807.09 |
| Travel and Lodging | $2,057.49 |
| Food and Beverage | $1,969.83 |
| Gift | $50.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $13,179.62 | 2019-2025 | Da Vinci Surgical System |
| Ethicon US, LLC | $10,501.66 | 2019-2025 | Enseal, Harmonic, Echelon; Endopath |
| Medical Device Business Services, INC. | $832.54 | 2024-2025 | Enseal |
| Medtronic, INC. | $392.45 | 2021-2025 | Interstim |
| Axonics, INC. | $180.96 | 2021-2023 | Axonics |
| Takeda Pharmaceuticals U.S.A., INC. | $110.88 | 2023 | Gattex |
| Conmed Corporation | $76.57 | 2023-2024 | Airseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Buzas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.